Literature DB >> 26148168

Ethical considerations in research. Focus on vulnerable groups.

Shaké Ketefian1.   

Abstract

The purpose of this paper was to describe the need to protect the rights of human subjects participating in nursing research, and procedures for doing so. The path taken to the task at hand was to approach the topic by discussing the philosophical underpinnings of human subject protection and describing the approach for doing this in all cases where humans are used as research subjects. These underpinnings include specific ethical principles of respect for persons, beneficence, and justice, and the procedures used in the U.S. for protecting the rights of human subjects. Once the process was clarified, the considerations necessary to protect the special groups referred to as ''vulnerable'' are discussed. Given the author's access to U.S. documents and the fact that U.S. government agencies took early steps to formalize rules and regulations for the protection of human subjects, vulnerable or otherwise, the experience of the United States was selected for presentation. It is recognized that there are now relevant international documents that are exceedingly helpful, and also, that various countries may have their own guidelines for investigators to follow. In such cases researchers can engage in comparative analysis between their own guidance and the processes described here, and decide their path accordingly.

Entities:  

Mesh:

Year:  2015        PMID: 26148168     DOI: 10.17533/udea.iee.v33n1a19

Source DB:  PubMed          Journal:  Invest Educ Enferm        ISSN: 0120-5307


  2 in total

1.  Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.

Authors:  Ling-Dan Dong; Xiang-Lin Cheng; Long Zhou; Qing Huang; Jun-Chuan Li; Cun-Jian Yi
Journal:  Oncol Lett       Date:  2017-02-08       Impact factor: 2.967

2.  Upregulation of the checkpoint protein CHFR is associated with tumor suppression in pancreatic cancers.

Authors:  Di Zhang; Xiao-Lan Xu; Fei Li; Hai-Chen Sun; Ye-Qing Cui; Shuang Liu; Ping-Yong Xu
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.